For healthy adult volunteers, safety and pharmacokinetic properties are compared between the two formulations in the case of HDDO-1756 alone administration and HDDO-17561/HDDO-17562 combined administration.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
56
single dose
single dose
Hyundai Pharm
Seoul, South Korea
pharmacokinetic evaluation variables
Cmax
Time frame: 0~96 hours
pharmacokinetic evaluation variables
AUC
Time frame: 0~96 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.